Chronos Archive seal
The Human Record

Jacqueline du Pré

Case HR-ML039-TD · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
26 January 1945 – 19 October 1987
Synthetic DOB
1945-01-26
Index visit
1973-03-09 at age 28
Synthetic MRN
HR-ML039-SYN-TD

Teaching objective: Recognize multiple sclerosis in a professional musician of 28 whose numbness and clumsiness of the fingers and fatigue could be put down to overwork or stress, as hers were for years, and care for it on the AAN 1965 disease-modifying therapy guideline, the ECTRIMS/EAN 1965 guideline and NICE NG220: urgent MRI of the brain and spine with gadolinium; diagnosis by the 1964 McDonald criteria (and their 1971 revision), with cerebrospinal fluid oligoclonal bands and exclusion of mimics (vitamin B12, thyroid, aquaporin-4 antibody for a myelitis; MOG antibody only when the picture suggests it); high-dose corticosteroids for a disabling relapse; early high-efficacy disease-modifying therapy, choosing among ocrelizumab, ofatumumab and natalizumab with JCV antibody status, infusion logistics and pregnancy plans; hepatitis B screening, immunoglobulins and vaccinations before B-cell therapy; vitamin D; infection and pseudo-relapse; fatigue; hand function with occupational therapy; and a plan built around her playing and teaching, set against the four years it took to name her illness in the 1970s, when no disease-modifying treatment existed.

Historical timeline

DateEventClaims
26 January 1945Born in Oxford, England.CLM-0001
March 1961Formal debut at Wigmore Hall, London, at 16, after the Suggia Award and the Queen's Prize.CLM-0002
1965Records the Elgar Cello Concerto.CLM-0003
June 1967Converts to Judaism and marries.CLM-0004
1971Loses sensitivity in her fingers; returns to England exhausted and takes a sabbatical; the numbness worsens on her return to the stage in 1972.CLM-0005, CLM-0006
February 1973Last public concerts, in London and New York.CLM-0007
October 1973Diagnosed with multiple sclerosis in London at 28; her performing career ends.CLM-0008, CLM-0010
1976Appointed OBE; teaches and gives master classes, and raises funds for MS research.CLM-0009, CLM-0011
19 October 1987Dies of multiple sclerosis in London at 42.CLM-0012

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Jacqueline Mary du Pré was born in Oxford, England, on 26 January 1945. Her mother was a pianist who had studied at the Royal Academy of Music, and her father an accountant. confirmed Jacqueline du Pré supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports
HISTMED Master Roster v3 context
D She began the cello as a small child, studied with William Pleeth at the Guildhall School of Music from the mid-1950s, won the Guilhermina Suggia Award at 11 in 1956 and the Queen's Prize at 15, attended a Pablo Casals masterclass in Zermatt in 1960, and made her formal debut at Wigmore Hall in London in March 1961, at 16.
Anchors the modern social history: a professional cellist since her teens.
confirmed Jacqueline du Pré supports
du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
D In 1965, at 20, she recorded Elgar's Cello Concerto with the London Symphony Orchestra under Sir John Barbirolli; she played chiefly on the Davidov Stradivarius of 1712.
Her documented career anchors the modern plan built around hand function and performance.
confirmed Jacqueline du Pré supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
D She converted to Judaism and married her husband, a pianist and conductor, in Jerusalem in June 1967.
History only; her husband is not named and is given no role in the modern episode.
confirmed Jacqueline du Pré supports
D In 1971 her playing declined as she began to lose sensitivity in her fingers and other parts of her body; she returned to England exhausted, took a sabbatical from 1971 to 1972 and performed only rarely. When she resumed in 1972 the numbness in her fingers worsened, with fatigue.
The anchor for the modern presenting problem (numbness and clumsiness of the hands, fatigue).
confirmed Jacqueline du Pré supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports
R Two physicians writing about her illness note episodes of blurred vision in her teens, which they read as possibly an early sign of multiple sclerosis.
Retrospective interpretation; not used as part of the modern history.
possible Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports
D Her last public concerts were in February 1973, in London, where she played the Elgar Concerto, and in New York.
Dates the end of her performing; the modern index visit follows it.
confirmed Jacqueline du Pré supports
Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports
D She was diagnosed with multiple sclerosis in London in October 1973, at 28, about four years after her first symptoms; the diagnosis ended her career as a performer.
The documented diagnosis to which the modern diagnosis is linked.
confirmed Jacqueline du Pré supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
D She went on teaching and giving master classes, singing or whistling the musical lines and explaining the fingering when she could no longer play, and remained a teacher and mentor until her death. She was appointed an Officer of the Order of the British Empire in the 1976 New Year Honours.
Her documented teaching anchors the modern plan built around her music.
confirmed du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports
Jacqueline du Pré supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
R Corticosteroids were the treatment available to her; physicians writing later judge that her illness followed a relapsing-remitting course that became secondary progressive.
Retrospective; the published reviews note that no medical records are public.
probable Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
D After her diagnosis and retirement she raised funds for multiple sclerosis research; fellowships in her name later funded travel grants for early-career MS researchers.
History only.
confirmed Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) supports
D She died of multiple sclerosis in London on 19 October 1987, at 42, and was buried in Golders Green Jewish Cemetery. One reference work gives 20 October.
The documented death from multiple sclerosis. History only, stated without detail.
confirmed Jacqueline du Pré supports
Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) supports
du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week resolved confirmed active CLM-0005, CLM-0007
S Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosis active confirmed both_with_link CLM-0008, CLM-0012, CLM-0010
S Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis active confirmed active CLM-0008, CLM-0012
S Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolved resolved confirmed active CLM-0008, CLM-0012

Synthetic outcome measures

GradeDateMeasureResultCoding
S 1973-03-09 Hemoglobin [Mass/volume] in Blood 13.4 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 1973-03-09 Leukocytes [#/volume] in Blood by Automated count 6.4 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1973-03-09 Lymphocytes [#/volume] in Blood by Automated count 1.9 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 1973-03-09 Platelets [#/volume] in Blood by Automated count 246 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 1973-03-09 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1973-03-09 Potassium [Moles/volume] in Serum or Plasma 4.2 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1973-03-09 Creatinine [Mass/volume] in Serum or Plasma 0.72 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1973-03-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M 117 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1973-03-09 Glucose [Mass/volume] in Serum or Plasma 86 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1973-03-09 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 16 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 1973-03-09 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 1973-03-09 Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 468 pg/mL
Reference 232-1245 pg/mL
http://loinc.org · 2132-9
S 1973-03-09 Thyrotropin [Units/volume] in Serum or Plasma 1.6 mIU/L
Reference 0.45-4.5 mIU/L
http://loinc.org · 3016-3
S 1973-03-09 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7
S 1973-03-09 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 26 s http://loinc.org · 83157-8
S 1973-03-09 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 33.5 s http://loinc.org · 83156-0
S 1973-03-23 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 16 ng/mL (low)
Reference Below 20 ng/mL deficient; 20 to 29 insufficient
http://loinc.org · 62292-8
S 1973-03-23 IgG [Mass/volume] in Serum or Plasma 1080 mg/dL
Reference 700-1600 mg/dL
http://loinc.org · 2465-3
S 1973-03-23 IgM [Mass/volume] in Serum or Plasma 124 mg/dL
Reference 40-230 mg/dL
http://loinc.org · 2472-9
S 1973-03-23 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 7 http://loinc.org · 44261-6
S 1973-03-23 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 6 http://loinc.org · 70274-6
S 1973-03-23 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 24.5 s http://loinc.org · 83157-8
S 1973-03-23 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 31 s http://loinc.org · 83156-0
S 1973-04-27 Hemoglobin [Mass/volume] in Blood 13.6 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 1973-04-27 Leukocytes [#/volume] in Blood by Automated count 7.9 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1973-04-27 Lymphocytes [#/volume] in Blood by Automated count 1.6 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 1973-04-27 Platelets [#/volume] in Blood by Automated count 252 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 1973-04-27 Glucose [Mass/volume] in Serum or Plasma 90 mg/dL
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1973-04-27 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 1973-04-27 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 1973-04-27 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 http://loinc.org · 44261-6
S 1973-04-27 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 20.5 s http://loinc.org · 83157-8
S 1973-04-27 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 23 s http://loinc.org · 83156-0
S 1973-06-15 Leukocytes [#/volume] in Blood by Automated count 10.2 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1973-06-15 C reactive protein [Mass/volume] in Serum or Plasma 14 mg/L (high)
Reference <=5 mg/L
http://loinc.org · 1988-5
S 1973-07-13 Hemoglobin [Mass/volume] in Blood 13.5 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 1973-07-13 Leukocytes [#/volume] in Blood by Automated count 6.1 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1973-07-13 Lymphocytes [#/volume] in Blood by Automated count 1.5 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 1973-07-13 Platelets [#/volume] in Blood by Automated count 240 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 1973-07-13 CD19 cells [#/volume] in Blood 3 /uL (low)
Reference 100-500 /uL
http://loinc.org · 8116-6
S 1973-07-13 IgG [Mass/volume] in Serum or Plasma 990 mg/dL
Reference 700-1600 mg/dL
http://loinc.org · 2465-3
S 1973-07-13 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 ng/mL
Reference Below 20 ng/mL deficient; 20 to 29 insufficient
http://loinc.org · 62292-8
S 1973-07-13 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 http://loinc.org · 44261-6
S 1973-07-13 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 19 s http://loinc.org · 83157-8
S 1973-07-13 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 20.5 s http://loinc.org · 83156-0
S 1973-09-14 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 1973-10-12 Hemoglobin [Mass/volume] in Blood 13.7 g/dL
Reference 12-15.5 g/dL
http://loinc.org · 718-7
S 1973-10-12 Leukocytes [#/volume] in Blood by Automated count 6 10*3/uL
Reference 4-11 10*3/uL
http://loinc.org · 6690-2
S 1973-10-12 Lymphocytes [#/volume] in Blood by Automated count 1.4 10*3/uL
Reference 1-4.8 10*3/uL
http://loinc.org · 731-0
S 1973-10-12 Platelets [#/volume] in Blood by Automated count 238 10*3/uL
Reference 150-400 10*3/uL
http://loinc.org · 777-3
S 1973-10-12 Creatinine [Mass/volume] in Serum or Plasma 0.7 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1973-10-12 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M 121 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1973-10-12 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 1973-10-12 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 U/L
Reference 8-35 U/L
http://loinc.org · 1920-8
S 1973-10-12 IgG [Mass/volume] in Serum or Plasma 930 mg/dL
Reference 700-1600 mg/dL
http://loinc.org · 2465-3
S 1973-10-12 IgM [Mass/volume] in Serum or Plasma 46 mg/dL
Reference 40-230 mg/dL
http://loinc.org · 2472-9
S 1973-10-12 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 ng/mL
Reference Below 20 ng/mL deficient; 20 to 29 insufficient
http://loinc.org · 62292-8
S 1973-10-12 Hepatitis B virus surface Ab [Units/volume] in Serum 6 m[IU]/mL (low)
Reference 10 mIU/mL or more is protective
http://loinc.org · 16935-9
S 1973-10-12 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 1973-10-12 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 http://loinc.org · 70274-6
S 1973-10-12 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 18.5 s http://loinc.org · 83157-8
S 1973-10-12 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 19.5 s http://loinc.org · 83156-0

Synthetic vital signs

DateMeasureResultLOINCGrade
1973-03-09Body height173 cm8302-2S
1973-03-09Body weight63.5 kg29463-7S
1973-03-09Body mass index (BMI) [Ratio]21.2 kg/m239156-5S
1973-03-09Systolic blood pressure112 mm[Hg]8480-6S
1973-03-09Diastolic blood pressure70 mm[Hg]8462-4S
1973-03-09Heart rate74 /min8867-4S
1973-03-09Respiratory rate14 /min9279-1S
1973-03-09Body temperature36.6 Cel8310-5S
1973-03-09Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
1973-03-23Body height173 cm8302-2S
1973-03-23Body weight63.4 kg29463-7S
1973-03-23Body mass index (BMI) [Ratio]21.2 kg/m239156-5S
1973-03-23Systolic blood pressure114 mm[Hg]8480-6S
1973-03-23Diastolic blood pressure72 mm[Hg]8462-4S
1973-03-23Heart rate76 /min8867-4S
1973-03-23Respiratory rate14 /min9279-1S
1973-03-23Body temperature36.7 Cel8310-5S
1973-03-23Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
1973-04-27Body height173 cm8302-2S
1973-04-27Body weight64.6 kg29463-7S
1973-04-27Body mass index (BMI) [Ratio]21.6 kg/m239156-5S
1973-04-27Systolic blood pressure118 mm[Hg]8480-6S
1973-04-27Diastolic blood pressure74 mm[Hg]8462-4S
1973-04-27Heart rate72 /min8867-4S
1973-04-27Respiratory rate14 /min9279-1S
1973-04-27Body temperature36.6 Cel8310-5S
1973-04-27Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
1973-07-13Body height173 cm8302-2S
1973-07-13Body weight64 kg29463-7S
1973-07-13Body mass index (BMI) [Ratio]21.4 kg/m239156-5S
1973-07-13Systolic blood pressure110 mm[Hg]8480-6S
1973-07-13Diastolic blood pressure70 mm[Hg]8462-4S
1973-07-13Heart rate70 /min8867-4S
1973-07-13Respiratory rate14 /min9279-1S
1973-07-13Body temperature36.6 Cel8310-5S
1973-07-13Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
1973-10-12Body height173 cm8302-2S
1973-10-12Body weight63.8 kg29463-7S
1973-10-12Body mass index (BMI) [Ratio]21.3 kg/m239156-5S
1973-10-12Systolic blood pressure112 mm[Hg]8480-6S
1973-10-12Diastolic blood pressure70 mm[Hg]8462-4S
1973-10-12Heart rate68 /min8867-4S
1973-10-12Respiratory rate14 /min9279-1S
1973-10-12Body temperature36.5 Cel8310-5S
1973-10-12Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
1973-06-15Body height173 cm8302-2S
1973-06-15Body weight63.6 kg29463-7S
1973-06-15Body mass index (BMI) [Ratio]21.3 kg/m239156-5S
1973-06-15Systolic blood pressure116 mm[Hg]8480-6S
1973-06-15Diastolic blood pressure72 mm[Hg]8462-4S
1973-06-15Heart rate92 /min8867-4S
1973-06-15Respiratory rate16 /min9279-1S
1973-06-15Body temperature37.8 Cel8310-5S
1973-06-15Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S
1973-09-14Body height173 cm8302-2S
1973-09-14Body weight63.9 kg29463-7S
1973-09-14Body mass index (BMI) [Ratio]21.4 kg/m239156-5S
1973-09-14Systolic blood pressure110 mm[Hg]8480-6S
1973-09-14Diastolic blood pressure70 mm[Hg]8462-4S
1973-09-14Heart rate68 /min8867-4S
1973-09-14Respiratory rate14 /min9279-1S
1973-09-14Body temperature36.6 Cel8310-5S
1973-09-14Oxygen saturation in Arterial blood by Pulse oximetry99 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

Care-plan goals

GoalTarget dateStatusOutcome
MRI of the brain and spine within one week and a neurology diagnosis within three weeks1973-03-23completedMRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks
High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations1973-04-27completedOcrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first
Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed1973-07-13completed19.0 seconds right and 20.5 seconds left at three months; practicing three hours a day
No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression)1973-10-12completedNo relapse; re-baseline MRI with no new or enhancing lesions; examination stable
25-hydroxyvitamin D of 30 ng/mL or more1973-07-13completed34 ng/mL after 16 weeks of cholecalciferol
PHQ-9 below 10 throughout1973-10-12completedPHQ-9 between 3 and 7

Interventions

InterventionStatusGuideline
Neurology (multiple sclerosis) consultation within two weeks to review the MRI with her and make a diagnosis and plancompletedGL-AAN-DMT-2018, GL-NICE-NG220
Urgent work-up of a sensory syndrome of both hands with Lhermitte's sign: MRI of the brain and cervical and thoracic spine with gadolinium within a week; blood count, chemistry, vitamin B12 and TSH; lumbar puncture for oligoclonal bands if the MRI is suggestive; return at once for weakness, unsteadiness, loss of bladder control or loss of visioncompletedGL-MCDONALD-2017, GL-MAGNIMS-2021, GL-NICE-NG220
Relapse treatment: methylprednisolone 1 g intravenously daily for three days for a relapse that limits her hand function, after excluding infection; occupational therapy for hand function and energy managementcompletedGL-NICE-NG220, GL-ECTRIMS-2018
Early high-efficacy disease-modifying therapy with ocrelizumab: 300 mg intravenously on days 1 and 15, then 600 mg every six months, with premedication; chosen over natalizumab because the JCV antibody is positive and over ofatumumab at her preference for twice-yearly infusions; before the first dose, hepatitis B screening, varicella and measles immunity, immunoglobulins, a pregnancy test, and inactivated vaccines at least two weeks ahead; contraception during treatmentcompletedGL-AAN-DMT-2018, GL-ECTRIMS-2018, GL-OPERA-2017, GL-AAN-VACC-2019
Vitamin D: cholecalciferol 4000 units daily to correct deficiency, with a level after three months; not as a treatment for multiple sclerosiscompletedGL-NICE-NG220
Monitoring on ocrelizumab: re-baseline MRI of the brain three to six months after starting, then yearly; blood count and immunoglobulins before each dose; infection and pseudo-relapse teaching; pregnancy planning, with conception timed after a dosecompletedGL-MAGNIMS-2021, GL-ECTRIMS-2018, GL-AAN-DMT-2018
Fatigue, mood and work: screening for depression and sleep problems at each visit, plain explanations with written information, and a plan built around her practice, performing and teaching; she decides who is told and who receives each notecompletedGL-NICE-NG220, GL-USPSTF-DEP-2023

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Tierradentro-García LO, Botero-Meneses JS, Talero-Gutiérrez C. The Sound of Jacqueline du Pré: Revisiting her Medical and Musical History. Mult Scler J Exp Transl Clin 2018;4(2):2055217318775756 (PMID 29780612) SAGE (Multiple Sclerosis Journal - Experimental, Translational and Clinical) scholarly
SRC-0002 Dacy LC, Rodriguez M. The interrupted concerto: Jacqueline du Pré and MS (Hektoen International, Fall 2014) Hektoen International: A Journal of Medical Humanities other
SRC-0003 Jacqueline du Pré Wikipedia other
SRC-0004 du Pré, Jacqueline (1945-1987) (Women in World History: A Biographical Encyclopedia) Encyclopedia.com (Gale) other
SRC-0005 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the application of the 2017 McDonald criteria and the 2024 revision, the decision to test aquaporin-4 but not MOG antibody, intravenous rather than oral methylprednisolone for the relapse, the choice of ocrelizumab over natalizumab (JCV antibody positive) and ofatumumab, the timing of vaccines before B-cell depletion, and the management of a pseudo-relapse with cystitis.
provenance reviewnot_startedShe died in 1987; the recent-death rule does not apply, but her husband and siblings are living or recently living public people and none of them is named; contested family accounts are not used. Claims rest on a 2018 peer-reviewed review, an essay by two Mayo Clinic physicians, Wikipedia and Women in World History; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail, and later disputed claims about it are not used. No relative is named or given a role in the modern episode.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.